Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
about
Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer.Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy.(A Critical Appraisal of) Classification of Hypereosinophilic Disorders.The European Vasculitis Society 2016 Meeting Report.Eosinophilic myocarditis as a first presentation of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).Eosinophils and eosinophil-associated diseases: An update.Biologic Agents for the Treatment of Hypereosinophilic Syndromes.Clinical and Biological Markers in Hypereosinophilic Syndromes.[Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)].Does the revised definition of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) indicate the need for a new treatment? Comment on the article by Puéchal et al.[S1 guidelines on diagnostics and treatment of ANCA-associated vasculitis].Towards precision medicine in ANCA-associated vasculitis.Investigational drugs in systemic vasculitis.Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.The Eosinophil: for better or worse, in sickness and in health.Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab.Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome.Eosinophils from Physiology to Disease: A Comprehensive Review.Current State and Future of Biologic Therapies in the Treatment of Asthma in ChildrenImmunological and hematological effects of IL-5(Rα)-targeted therapy: An overviewBenralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid useTherapeutic Management of Pediatric Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
P2860
Q41098587-865386AA-128F-4D06-80B2-3CED7584B25FQ46152183-0EE15C6B-11D5-438F-870F-B85E95998C77Q47094850-7A0D4C79-59C0-4F25-AC9C-1855C2D58DCEQ47107377-08D36DE7-8ECC-4900-B09D-D791AE84404EQ47114877-D31F345A-BD26-44D1-8CF9-3F272CCF2326Q47566949-7E2D9D8A-BEAC-4D3D-9855-97472671191AQ47848286-9B7278EC-B238-4139-ABB5-E6C7A7537543Q49248245-CE6F3BCE-3E75-4F35-B8F6-7D3D7D81ADA9Q49567785-94AD2F0B-AEF5-4BE0-B9E6-77D1A6EF8031Q49820442-56C517FF-8659-4ED6-A0BB-B0D5850C0B29Q50086076-1796E987-2F25-43A5-A480-F224BF845C01Q50089937-0A3CABAB-F771-41CD-A388-EBFE6554EE79Q51834131-897FAD62-7698-4E35-A546-5AC7244EE81DQ52571066-C653720B-A38B-4E2B-8CCD-4606E68DC911Q52729256-D63792CA-68BB-4A49-A5C6-649CB65AF45DQ55009792-550FB023-6069-42CB-862D-43E75AE97EFFQ55115543-250E8466-A9F0-495A-BAA0-C9AE33A395AEQ55311740-30287DBE-8C00-4E73-A97B-9C30C2BCEC69Q57128935-B175880E-ACDC-4160-BA79-C201D3CDADD1Q58693435-DAA018A1-1E59-4982-9535-D97A465C0836Q58698606-76F42C0B-57AD-4CC7-A642-ADC006F48C7FQ59160663-9BFCF37D-5F70-4558-AB12-37C9E583EBB6
P2860
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
@en
type
label
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
@en
prefLabel
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
@en
P2093
P2860
P356
P1476
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
@en
P2093
Carol A Langford
David Jayne
EGPA Mepolizumab Study Team
Frank Moosig
Gerald J Gleich
Jonathan Steinfeld
Judith Brown
Maria C Cid
Michael E Wechsler
P2860
P304
P356
10.1056/NEJMOA1702079
P407
P577
2017-05-01T00:00:00Z